Regulatory ApprovalsGeographic expansion continues with approval in Japan for ALGS and PFIC.
Revenue GrowthThe company generated $336M in product revenue in 2024, an 88% YoY increase, driven by robust clinical demand across indications and international market expansion.
Sales And PerformanceLivmarli sales of $73.2M were above consensus and expectations, indicating continued momentum.